Serious conditions behind bloody cough symptoms revealed. Life-threatening diseases that cause alarming blood in cough ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

The approval of sunvozertinib, an oral irreversible EGFR inhibitor, was supported by data from the WU-KONG1B trial (ClinicalTrials.gov Identifier: NCT03974022 ). The primary efficacy population ...

AstraZeneca PLC (AZN) and Summit Therapeutics Inc (SMMT) are reportedly discussing a $15 billion partnership to license the ...

An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable ...

The FDA has granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( ...

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...

Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a potential $15 billion ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Long-term antihypertensive therapy was not associated with risk for cancer, cancer-related mortality or site-specific cancers ...

Nearly a quarter of all newly-diagnosed patients with advanced lung cancer are not given a test that could improve their chances for long-term survival and reduce their side effects.

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...